This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB03783/identifier/chebi/
n17http://linked.opendata.cz/resource/mesh/concept/
n19http://linked.opendata.cz/resource/drugbank/drug/DB03783/identifier/wikipedia/
n20http://linked.opendata.cz/resource/drugbank/drug/DB03783/identifier/pharmgkb/
n13http://linked.opendata.cz/resource/drugbank/drug/DB03783/identifier/kegg-compound/
n11http://linked.opendata.cz/resource/drugbank/drug/DB03783/identifier/pubchem-compound/
n6http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB03783/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB03783/identifier/kegg-drug/
n9http://linked.opendata.cz/resource/drugbank/drug/DB03783/identifier/drugbank/
n18http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n16http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/drugbank/drug/DB03783/identifier/chemspider/

Statements

Subject Item
n2:DB03783
rdf:type
n3:Drug
n3:description
Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).
n3:generalReferences
# Dubach UC, Rosner B, Sturmer T: An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987) N Engl J Med. 1991 Jan 17;324(3):155-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1984193 # Cochran AJ, Lawson DH, Linton AL: Renal papillary necrosis following phenacetin excess. Scott Med J. 1967 Jul;12(7):246-50. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6036245 # TAN GH, RABBINO MD, HOPPER J Jr: IS PHENACETIN A NEPHROTOXIN?A REPORT ON TWENTY-THREE USERS OF THE DRUG. Calif Med. 1964 Aug;101:73-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14180501 # Brix AE: Renal papillary necrosis. Toxicol Pathol. 2002 Nov-Dec;30(6):672-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12512867
n3:group
withdrawn
n3:indication
Used principally as an analgesic.
owl:sameAs
n6:DB03783 n18:DB03783
dcterms:title
Phenacetin
adms:identifier
n8:4590 n9:DB03783 n10:8050 n11:4754 n12:46507394 n13:C07591 n14:D00569 n19:Phenacetin n20:PA450897
n3:mechanismOfAction
Phenacetin's analgesic effects are due to its actions on the sensory tracts of the spinal cord. In addition, phenacetin has a depressant action on the heart, where it acts as a negative inotrope. It is an antipyretic, acting on the brain to decrease the temperature set point. It is also used to treat rheumatoid arthritis (subacute type) and intercostal neuralgia. [Wikipedia]
n3:synonym
Acetophenetin Acetphenetidin Acetophenetidine Acetophenetidin
n3:toxicity
Acute oral toxicity (LD50): 866 mg/kg [Mouse].
n3:synthesisReference
Ernst Bocker, Wolfgang Kracht, Roland Rupp, Erhard Schellmann, Viktor Trescher, Martin Ullrich, "Preparation of melt-sprayed spherical phenacetin granules." U.S. Patent US4086346, issued October, 1972.
n16:hasConcept
n17:M0016487
n3:IUPAC-Name
n4:271B41F4-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B41FA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B41F9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B41F6-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B41F7-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B41F8-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B41F2-363D-11E5-9242-09173F13E4C5 n4:271B420A-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B41F3-363D-11E5-9242-09173F13E4C5 n4:271B41F0-363D-11E5-9242-09173F13E4C5 n4:271B420C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B41F1-363D-11E5-9242-09173F13E4C5 n4:271B420D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4200-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4201-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B41FB-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B41FC-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B41FE-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B41FD-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B41FF-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
62-44-2
n3:category
n3:Bioavailability
n4:271B4206-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4208-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4209-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B420B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4205-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4204-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4207-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B41F5-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4202-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4203-363D-11E5-9242-09173F13E4C5